Chronic Disease  >>  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
NCT01691547: A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

Completed
1
44
US
UMEC /VI, UMEC, VI, FF
GlaxoSmithKline, Parexel
Pulmonary Disease, Chronic Obstructive
03/13
03/13
NCT01894386: Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Completed
1
48
US
FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
09/13
09/13
NCT02837380: A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects

Completed
1
16
RoW
FF, VI/UMEC
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
11/16
11/16

Download Options